
Reset all filters
01 7Bevespi
02 10Breztri
03 3Brovana
04 4Cortiment
05 5Duaklir
06 9Dulera
07 1Eohilia
08 1Foradil
09 11Pulmicort
10 23Symbicort
11 5Uceris
12 1Uceris/Cortiment
13 1Ultibro Group
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 6
2019 Revenue in Millions : 11
Growth (%) : -48
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 8
2019 Revenue in Millions : 5
Growth (%) : 70
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 0
2019 Revenue in Millions : 213
Growth (%) : -100
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 0
2019 Revenue in Millions : 213
Growth (%) : -100
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 2,721
2019 Revenue in Millions : 2,495
Growth (%) : 9
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 48
2019 Revenue in Millions : 42
Growth (%) : 14
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 2,721
2019 Revenue in Millions : 2,495
Growth (%) : 9
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 996
2019 Revenue in Millions : 1,466
Growth (%) : -32
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 28
2019 Revenue in Millions : 2
Growth (%) : 1,300
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 4
2020 Revenue in Millions : 7
Growth (%) : -42